AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06455306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Air-polishing with erythritol
Description: The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
Study NCT05248503 — intervention group
Intervention type: BEHAVIORAL
Intervention: Complex Care Training of Hereditary Epidermolysis Bullosa
Description: Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
Study NCT05889442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Description: Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
Study NCT05889442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
Study NCT04720716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 IV d1, Q6W
Study NCT04720716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: sintilimab IV d1, Q3W
Study NCT04720716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400mg po
Study NCT05400109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UF-KURE19 CAR-T cells
Description: UF-KURE19 cells are initially generated from a starting autologous apheresis sample. T cells are activated and transduced with Kure19 lentiviral vector that consists of a 3rd generation vector with an scFV (FMC63) that targets CD19. The product is harvested at 17-20hr after culture and cryopreserved
Study NCT05400109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
Study NCT05400109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The mechanism of action is thought to involve cross-linking of tumor cell DNA
Study NCT06031714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sampling
Description: HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
Study NCT06031714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.
Study NCT06031714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: V2 and/or V3
Study NCT06031714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination
Description: V2 and/or V3
Study NCT05352854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% pilocarpine eye drops
Description: Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
Study NCT06501027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Self Compassion
Description: The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
Study NCT05561491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: Oncolytic virus
Study NCT05561491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Anti PD-1
Study NCT05469516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System [Ulthera, Inc.]
Description: The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis
Study NCT05585528 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional or surgical management in 1st intention
Description: Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
Study NCT05607030 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VT-X7 Treatment System
Description: Seven-day local antibiotic irrigation (alternating vancomycin hydrochloride and tobramycin sulfate) via the temporary VT-X7 Knee or Hip Spacer.
Study NCT05607030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.
Study NCT04083170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04083170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04083170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT04083170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04083170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT
Study NCT05607030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage exchange arthroplasty
Description: Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis.
Study NCT05607030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC Antibiotics
Description: Administration of at least 6 weeks of systemic antibiotics post-Stage 1 surgery followed by a 2-week antibiotic holiday before the Stage 2 surgery. After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Study NCT05607030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Antibiotics
Description: After Stage 2 surgery, administration of at least 12 weeks of systemic antibiotics. Antibiotics will be selected by the treatment provider based on the infecting organism and administered per national and local treatment guidelines.
Study NCT05393024 — intervention group
Intervention type: DRUG
Intervention: Belantamab mafodotin
Description: MMRR patients included in Named Patient Program e Expanded Access Program
Study NCT05117242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: Acasunlimab will be administered intravenously (IV)
Study NCT05117242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV
Study NCT05469516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merz Radiesse Injectable Implant
Description: Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
Study NCT04851782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivEAD tubing kit
Description: ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
Study NCT04984889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-662
Description: Lyophilized, sterile concentrate of human protein C
Study NCT06671353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video decision aid
Description: video decision aid for advance care planning
Study NCT04083170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dilanubicel
Description: Given IV
Study NCT04502394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
Study NCT04983004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-rehabilitation
Description: According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
Study NCT04983004 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bedside rehabilitation
Description: The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
Study NCT06690242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1013
Description: MT1013 is a novel calcimimetic agent
Study NCT06690242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etelcalcetide Hydrochloride
Description: the already-marketed therapeutic agents
Study NCT06690242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The measure does not contain the active ingredients
Study NCT06692998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
Study NCT05230069 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Patients will be interviewed post an emergency call and evaluation.
Study NCT05791669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
Study NCT05791669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish
Description: It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
Study NCT06579287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ002
Description: Topical ophthalmic
Study NCT06692998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
Study NCT05659459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN001
Description: Oral tablet
Study NCT05659459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KIN001-Placebo
Description: Comparator - Oral tablet with same appearance of KIN001
Study NCT06700252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: This intervention used gaze stabilization, habituation, balance training and exertional training. Exercises utilized included visual tracking, gaze holding with head turns, saccades, visual accommodation exercises, visual convergence exercises, positional accommodation, rockerboard proprioception, single leg balance on the floor and on dynamic surfaces, tandem balance on the floor and on dynamic surfaces, double leg balance on dynamic surfaces, mirror feedback of functional activities, and physical exertion training with walking, biking or sport specific activities.
Study NCT06700252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Protocol
Description: This intervention symptom management and graduated return to physical activity involving a stepwise progression in which the participant proceeded to the next step if symptom-free at the current step for a 24-hour period. If any symptoms occurred at that step, the participant was returned to the previous step and tried to progress again after 24 hours of rest. The steps were as follows: 1) Patient to return to regular activities such as school 2) Light aerobic activity to increase the patient's heart rate achieved with 5 to 10 minutes on a stationary bike or walking but without weightlifting 3) Moderate activity which increased the heart rate with head or body movement that may have included sport specific exercise with minimal-moderate resistance 4) Heavy, non-contact activity in three planes of movement 5) Full contact practice 6) Competition
Study NCT06699628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRL757
Description: IRL757 capsules
Study NCT06579287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Topical ophthalmic
Study NCT04819438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg Oral Film
Description: Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
Study NCT04819438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilutek 50Mg Tablet
Description: One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
Study NCT04875507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychology
Description: This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
Study NCT05132998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program
Description: In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
Study NCT05132998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community exercise intervention
Description: In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
Study NCT06148740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Health Pro Vitality Daily Restorative Face Serum with Propolis & Vitamin C
Description: Skin serum containing propolis, vitamin C, and manuka honey.
Study NCT05296460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone gel
Description: The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
Study NCT06387810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome II combined with 5-FU/LV and oxaliplatin
Description: irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs.
Study NCT06553716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess
Description: The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
Study NCT06553716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess
Description: The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
Study NCT06059872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
Study NCT05689606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise includes acute high-intensity interval training.
Study NCT05320094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Specified dose on specified days
Study NCT05320094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal with Sorbitol
Description: Specified dose on specified days
Study NCT05646407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honeywell HT-900 Turbo Force Air Circulator
Description: This is a basic, portable, household fan with a single cost of CDN$21.99.
Study NCT06428565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) or cold laser therapy
Description: Low-level laser therapy (LLLT) or cold laser therapy
Study NCT05724160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Using sitting ellipticals
Description: Patients will receive routine physiotherapy protocols as well as Non-weightbearing stationary elliptical
Study NCT05724160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy Protocol
Description: Routine physiotherapy protocol
Study NCT05749003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensorimotor training exercise
Description: Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
Study NCT05749003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy program of exercise.
Description: stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
Study NCT05749003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program of exercise.
Description: stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
Study NCT06390410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: 100 mg PTI-125
Study NCT05068557 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).
Description: Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
Study NCT04118036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenously over 30 minutes every 21 days (+/- 3 days)
Study NCT04118036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Oral 2 times a day